8-K: STRATA Skin Sciences Q2 Revenue Down 9%; Focus on New Reimbursement Codes

STRATA Skin Sciences reported a 9% decline in second-quarter revenue to $7.7 million, alongside an increased net loss, while emphasizing strategic growth through expanded reimbursement codes for its XTRAC laser treatment.

Summary

• Revenue for Q2 2025 was $7.7 million, a 9% decrease compared to Q2 2024.
• Global recurring revenue declined 4% year-over-year to $5.1 million, and equipment revenue decreased 18% year-over-year to $2.5 million.
• Gross profit was $4.3 million, or 56% of revenue, down from $5.0 million in Q2 2024.
• Net loss for Q2 2025 was $2.5 million, or negative $0.60 per basic and diluted common share, significantly wider than the $0.1 million net loss (negative $0.03 EPS) in Q2 2024.
• The company ended Q2 2025 with $6.0 million in cash and cash equivalents.
• Adjusted for a $1.3 million restricted cash payment to NY state for sales tax accrual and approximately $340 thousand in legal expenses, the company was nearly operating cash flow breakeven for the quarter.
• Historic expansion of CPT codes for inflammatory and auto-immune skin diseases is expected to more than triple the covered patient population in the US.
• Average gross billings per device increased 2.7% over the prior-year period to $5,512.
• 19 XTRAC devices were placed, the highest number of placements in six quarters, while 21 underperforming devices were removed.

Sentiment

Score: 3

Explanation: While the company highlights strategic positives like CPT code expansion and IP, the financial results for the quarter show significant deterioration with declining revenue, widening net losses, and increased operating expenses. The positive outlook is forward-looking and not yet reflected in current performance, indicating a challenging financial position despite strategic efforts.

Positives

• Historic expansion of CPT codes for inflammatory and auto-immune skin diseases, potentially tripling the covered patient population in the US.
• Application for G-codes could accelerate expanded reimbursement coverage by the 2026 cycle.
• Submission of economic data to support a potential increase in reimbursement rates.
• New peer-reviewed publications validating vitiligo indication and reimbursement.
• Multiple peer-reviewed publications on the conjunctive use of excimer laser with JAK inhibitors, illustrating safety, efficacy, and synergistic effects, with intellectual property held around these methods.
• Positive developments in the ongoing lawsuit against LaserOptek, with LaserOptek Korea and C. Dalton, LLC added as defendants.
• Average gross billings per device increased 2.7% over the comparable prior-year period to $5,512.
• Placed 19 XTRAC devices, the highest number of placements in six quarters.
• Nearly operating cash flow breakeven in the quarter when adjusting for a $1.3 million restricted cash payment to NY state and approximately $340 thousand in legal expenses.
• Maintained $6.0 million in cash despite the $1.3 million payment to NY state.

Negatives

• Revenue for Q2 2025 decreased 9% to $7.7 million compared to Q2 2024.
• Global recurring revenue declined 4% year-over-year to $5.1 million.
• Equipment revenue decreased 18% year-over-year to $2.5 million.
• Gross profit decreased to $4.3 million (56% of revenue) from $5.0 million in Q2 2024.
• Total operating expenses increased to $6.5 million from $5.5 million in the prior-year period.
• Net loss significantly widened to $2.5 million (negative $0.60 EPS) in Q2 2025, compared to a net loss of $0.1 million (negative $0.03 EPS) in Q2 2024.
• Q2 2024 earnings benefited from $864 thousand from the CARES Act, which was not present in Q2 2025.
• Net cash used in operating activities for the six months ended June 30, 2025, was $(2,491) thousand, a significant increase from $(213) thousand in the prior-year period.
• Total stockholders' equity decreased from $4,972 thousand at December 31, 2024, to $308 thousand at June 30, 2025.

Risks

• Financial, economic, business, competitive, market, and regulatory uncertainties.
• Adverse market conditions, labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the company, the medical device industry, and customers/patients.
• Risks related to the company's ability to launch and sell recently acquired or future developed products.
• Challenges in developing social media and direct-to-consumer marketing campaigns.
• Risks associated with building a leading franchise in dermatology and aesthetics.
• Seasonality of the business, specifically slower first and second quarters.

Future Outlook

The company anticipates that the historic expansion of CPT codes and the application for G-codes will more than triple the available patient population for its XTRAC Excimer laser treatment, leading to an extremely positive outcome for the company's bottom line despite expected seasonality in the first and second quarters. Management plans to continue carefully managing costs, strategically expanding the patient pool through direct-to-consumer efforts, and strengthening practice partners through consulting services.

Management Comments

• "STRATA continues to execute on our growth strategy, taking advantage of newly approved reimbursement codes in new indications for our XTRAC Excimer laser treatment."
• "As we announced, these revised reimbursement code descriptors, and the temporary codes weve applied for, have the potential to more than triple our available patient population by expanding into new indications."
• "While we will continue to deal with the seasonality of our business specifically a slower first and second quarter we anticipate the overall outcome to be extremely positive for STRATAs bottom line."
• "In the meantime, we continue to carefully manage costs and strategically expand our patient pool through our DTC efforts, while strengthening our practice partners through our consulting services."

Industry Context

The medical technology industry, particularly in dermatology, is seeing advancements in treatment paradigms, such as the conjunctive use of excimer lasers with JAK inhibitors, which STRATA is actively pursuing with intellectual property. The expansion of CPT codes for inflammatory and auto-immune skin diseases reflects a broader trend towards increased reimbursement coverage for advanced dermatologic treatments, potentially opening up significant market opportunities for companies like STRATA that offer specialized devices like the XTRAC laser. The focus on direct-to-consumer marketing and practice partner support indicates a competitive landscape where companies are striving to capture market share and enhance physician adoption.

Comparison to Industry Standards

• NA

Legal Proceedings

• Ongoing lawsuit against LaserOptek, with positive developments including the addition of LaserOptek Korea and C. Dalton, LLC as defendants.

Stakeholder Impact

• Shareholders: Negative impact due to significant net loss, declining revenue, and reduced stockholders' equity. Potential positive long-term impact if strategic initiatives (reimbursement codes, IP) succeed.
• Customers (Dermatology Practices): Positive impact through the Partnership Program, which includes fee-per-treatment, device installation, training, service, and co-op advertising support. Potential for increased patient volume due to expanded reimbursement codes.
• Patients: Positive impact from expanded access to XTRAC Excimer laser treatment for inflammatory and auto-immune skin diseases due to CPT code expansion and potential G-code access.
• Employees: No direct impact mentioned, but financial performance could indirectly affect future stability or growth opportunities.

Next Steps

• Continue to execute on growth strategy, leveraging newly approved reimbursement codes.
• Pursue G-code application for accelerated expanded reimbursement coverage by the 2026 cycle.
• Continue to manage costs carefully.
• Strategically expand patient pool through direct-to-consumer (DTC) efforts.
• Strengthen practice partners through consulting services.
• Continue ongoing lawsuit against LaserOptek.

Key Dates

Recommendation

While the financial results for Q2 2025 show significant deterioration with declining revenue and a widening net loss, the company has announced strategic initiatives that could be transformative, particularly the expansion of CPT codes and the pursuit of G-codes, which have the potential to triple the addressable patient population. The positive developments in the LaserOptek lawsuit and the increase in average gross billings per device are also encouraging. However, the current financial performance indicates a challenging period. An investor should 'hold' to monitor the execution and impact of these strategic initiatives, especially the realization of increased patient volume and reimbursement rates, before making a more definitive investment decision. The current financial weakness suggests caution, but the long-term potential from the strategic shifts warrants not selling immediately.

Keywords

Dermatology, Medical Technology, Excimer Laser, XTRAC, Psoriasis, Vitiligo, Acne Therapy, Reimbursement Codes, CPT Codes, JAK Inhibitors, Skin Diseases, Healthcare, Medical Devices, STRATA Skin Sciences